First Horizon Advisors’s Pacira BioSciences PCRX Stock Holding History

First Horizon Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-445	Closed	-$12.7K	–	2381
2024 Q2	$12.7K	Buy	445 +12	+3%	+$342	﹤0.01%	1435
2024 Q1	$12.7K	Hold	433	–	–	﹤0.01%	1505
2023 Q4	$14.6K	Hold	433	–	–	﹤0.01%	1452
2023 Q3	$13.3K	Hold	433	–	–	﹤0.01%	1405
2023 Q2	$17.4K	Hold	433	–	–	﹤0.01%	1323
2023 Q1	$17.7K	Hold	433	–	–	﹤0.01%	1306
2022 Q4	$16.7K	Sell	433 -3	-0.7%	-$146	﹤0.01%	1318
2022 Q3	$23K	Hold	436	–	–	﹤0.01%	1178
2022 Q2	$25K	Buy	436 +433	+14,433%	+$28.4K	﹤0.01%	1204
2022 Q1	$0	Sell	3 -433	-99%	-$28.9K	﹤0.01%	2138
2021 Q4	$26K	Sell	436 -127	-23%	-$7K	﹤0.01%	1184
2021 Q3	$31K	Buy	563 +286	+103%	+$16.5K	﹤0.01%	1108
2021 Q2	$16K	Hold	277	–	–	﹤0.01%	1193
2021 Q1	$19K	Sell	277 -91	-25%	-$6.5K	﹤0.01%	1099
2020 Q4	$22K	Buy	368 +172	+88%	+$10.1K	﹤0.01%	867
2020 Q3	$11K	Buy	+196	New	+$11.4K	﹤0.01%	983

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

First Horizon Advisors's PCRX Position: Q3 2024 in Review

First Horizon Advisors sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 445 shares — an estimated $12.7K sold.

First Horizon Advisors first reported a position in PCRX in Q3 2020 and held it in 16 quarters. The position peaked at $31K in Q3 2021. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

First Horizon Advisors reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
First Horizon Advisors sold 445 Pacira BioSciences shares in Q3 2024, an estimated $12.7K.
First Horizon Advisors first reported a position in Pacira BioSciences in Q3 2020 and held it in 16 quarters.
First Horizon Advisors's Pacira BioSciences position peaked at $31K in Q3 2021.
239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on First Horizon Advisors's 13F filing for Q3 2024, filed 8 Nov 2024.